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A Break in the Brake Mechanism in
Diabetes
A cause of postprandial hyperglycemia
T
he importance of insulin and gluca-
gon as ﬁne regulators of glycemic
excursions is well established (1).
Alterations in gastric emptying are gener-
ally not considered important contribu-
tors to postprandial hyperglycemia until
latecomplicationsofdiabetessuchasgas-
troparesis have occurred (2,3). It is now
emerging that the rate of gastric emptying
may be a major determinant of postpran-
dial glycemic excursions in healthy sub-
jects, as well as in type 1 and type 2
diabetic patients (4).
Gastroparesis is a relatively rare com-
plication that occurs late in diabetes be-
cause of irreversible intestinal nerve
damage(4);itmustbedistinguishedfrom
the physiological inhibitory effects of
acute hyperglycemia on gastric motility
(5,6). The latter has been proposed as a
defense mechanism existing to minimize
postprandial hyperglycemia by reducing
the rate of efﬂux of glucose into the circu-
lation from the gut (7). This may be of
special importance for people with type 1
diabeteswhohaveareducedabilitytode-
laygastricemptyinginresponsetohyper-
glycemia (8). Cross-sectional studies
suggest that an inverse relationship be-
tween the rate of gastric emptying and
blood glucose concentration also exists in
type2diabeticpatients(4)and,thus,that
similar regulatory mechanisms may exist
in both conditions.
Regulation of gastric emptying
Extrinsicpathway. Normally,therateof
gastric emptying is tightly regulated as a
result of neural and hormonal feedback
triggered by the interaction of nutrients
within the small intestine known as the
ileal break mechanism or “extrinsic path-
way” of control. This feedback is caloric-
load dependent, relates to the length of
small intestine exposed to nutrient, and
regulates the overall rate of emptying to
about 2–3 kcal/min (9,10). When food
reaches the intestine, L- and K-cells in the
distal small bowel are stimulated to pro-
duce glucagon-like peptide 1 (GLP-1)
and glucose-dependent insulinotropic
peptide(GIP),respectively,bothofwhich
exerttheireffectsondifferenttargets(11).
In the brain, they act on the hypothala-
mus, reducing appetite; they also send
signals via cholinergic and peptidergic
neurotransmission in the vagus nerve di-
rectly to the stomach, inhibiting antral
motility and stimulating pyloric motility,
both of which contribute to inhibition of
gastric emptying (12). GLP-1 and GIP
stimulate glucose-dependent insulin re-
lease from pancreatic islet -cells, as well
as human islet amyloid pancreatic pep-
tide (hIAPP), and simultaneously inhibit
glucagon secretion from pancreatic
-cells. Insulin plays a role in the reduc-
tion of food intake through an action in
the satiety center in the hypothalamus,
whereashIAPPslowsgastricemptying,an
action mediated by the central nervous
system requiring an intact vagus nerve
andareapostrema(13).Incontrast,nitric
oxide (NO) is an important neurotrans-
mitterinthegutandhasbeendemonstrated
to be a key physiological mediator of non-
adrenergic noncholinergic (NANC) relax-
ation of gastrointestinal smooth muscle
(14) of the stomach, pylorus, and the du-
odenum, thereby facilitating gastric emp-
tying by partially inhibiting pyloric and
proximal duodenal contractions (15).
The ﬁnal outcome on the rate of gastric
emptyingandthepreventionofpostpran-
dial hyperglycemia is clearly dictated by a
delicate balance between these opposing
forces.
Intrinsic pathway. The intrinsic path-
way is dependent upon the action of
hyper-orhypoglycemiaongastricemp-
tying. Hyperglycemia stimulates secre-
tion of insulin and hIAPP and inhibits
the secretion of glucagon from the pan-
creas and ghrelin from the stomach
(16). The increase in hIAPP and de-
crease in ghrelin both slow the gastric
emptying rate by producing a parasym-
patheticsignal(17).Ghrelinsecretionis
stimulated by cholecystokinin and gas-
trin, and it in turn enhances antropylo-
ric coordination, a signal transmitted
via the vagus nerve (18), which acceler-
ates gastric emptying (19). Ghrelin, in
addition,actsonthesatietycenterinthe
hypothalamus to enhance food intake
(20). Hypo- and hyperglycemia can act
directly in the hypothalamus, increas-
ing or decreasing appetite respectively
(21),buttheyalsoactivatetheparasym-
pathetic system and send signals to in-
crease (hypoglycemia) (22) or decrease
(hyperglycemia) (23) the gastric empty-
ing rate.
Regulation of gastric emptying in
diabetes
Before the advent of autonomic neuropa-
thy, rapid gastric emptying is seen in
subgroups of patients in the early stages
of non–insulin-dependent diabetes
(type 2 diabetes), and neuropathy-free,
insulin-dependent diabetes (type 1 dia-
betes)(19).Solidgastricemptyingisac-
celerated in obese type 2 diabetic
patients without overt autonomic neu-
ropathy when compared with obese
nondiabetic patients (24). In diabetes,
there is impaired meal-induced relax-
ation of the gastric fundus, increased
pyloric motor activity, fewer antral con-
tractions, and impaired antroduodenal
coordination. Disturbances of the gas-
tric electrical rhythm, measured by
electrogastrography, also occur fre-
quently (9). Hence, the extrinsic ileal
break mechanism may be impaired in
diabetes.
In this issue, Woerle et al. (25) ex-
amine the intrinsic brake mechanism
and report that slowing of gastric emp-
tying by hyperglycemia may be im-
paired in patients with type 1 diabetes.
In this study, consequences of eugylcemia-
and hyperglycemia-induced changes in
gastric emptying on postprandial glucose
ﬂuxes and excursions were seen in 10
healthy subjects and 15 type 1 diabetic
subjects after ingestion of a mixed meal
using the double isotope approach
([6,6-
2H2]and[1-
13C]glucose)andscin-
tigraphic measurements of gastric empty-
ing. It was found that gastric emptying
was greater in type 1 diabetic subjects
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markedly delayed gastric emptying in
healthy subjects but did not alter it in
type 1 diabetic subjects. Plasma IAPP
increased approximately fourfold in
healthy subjects, whereas it was unde-
tectable in type 1 diabetic subjects.
IAPP replacement using the analogue of
IAPP, pramlintide, in type 1 diabetic
subjects slowed gastric emptying to a
comparable extent—as did hyperglyce-
mia in healthy subjects—and greatly re-
duced postprandial hyperglycemia.
Meal-derived glucose appearance in
plasma was reduced and splanchnic
glucose sequestration increased.
Woerle et al. concluded that in pa-
tients with type 1 diabetes, the ability to
delay gastric emptying in response to hy-
perglycemiaisimpaired.Thisimpairment
contributes to exaggerated rates of meal-
derived glucose appearance and, ulti-
mately, postprandial glucose excursions.
Thepancreatic-cellhormonehIAPP
is cosecreted with insulin in a ﬁxed molar
ratio (26) and has potent inhibitory ef-
fects on gastric emptying (27). Thus, pa-
tientswithtype1diabetes,eveniftheyare
without concomitant enteric neuropathy,
should have increased rather than de-
layed rates of gastric emptying because
they are hIAPP deﬁcient (28). This may
also apply in type 2 diabetes, wherein se-
cretion of hIAPP is impaired before insu-
lin secretion (29).
Hyperglycemia has been reported to
cause profound inhibition of vagal activ-
ity accompanied by substantial hIAPP
secretion (30). In contrast, in IAPP-
deﬁcient patients with type 1 diabetes,
hyperglycemia did not affect vagal ac-
tivity (8). Because the inhibitory effect
of IAPP on gastric emptying seems to be
mediated via inhibition of vagal nerve
activity(30),theobservationsofWoerle
et al. are consistent with the concept
that a hyperglycemia-induced delay in
gastric emptying may be at least par-
tially regulated via an IAPP-mediated
inhibitory effect on vagal nerve activity
(27).
Teleologically, the slowing of gastric
emptying during hyperglycemia can be
seen as an important defense mechanism
preventing hyperglycemia. hIAPP secre-
tion is linked to insulin release (26). As a
response to hyperglycemia, the pancre-
atic -cell, with its glucose sensor, in-
creases insulin and IAPP secretion.
Insulinsuppresseshepaticglucoseoutput
and increases peripheral glucose uptake
(31).
Takingthisintoconsideration,hIAPP
deﬁciency may be seen as one cause for
the unresponsiveness to delayed gastric
emptying. To prove that IAPP deﬁciency
is the sole reason for unresponsiveness to
a hyperglycemia-induced delay in gastric
emptying, direct inhibition of the IAPP
effects using a speciﬁc antagonist would
be required to fulﬁll Koch’s postulates.
As indicated above, there are other
candidates for the regulator role of the
brake mechanisms. Ghrelin levels rise in
the circulation before and decrease after a
meal (32). The postprandial suppression
of ghrelin levels 30–60 min after a meal
were signiﬁcantly lower in obese patients
than in normal-weight patients. Plasma
ghrelin levels are, hence, elevated in dia-
betes. Elevated endogenous ghrelin en-
hances antropyloric coordination, which
accelerates gastric emptying in the early
stages of diabetes (19). This, together
with the role of NO as an accelerator of
gastric emptying, suggests that deﬁning
the complexity of loss of the brake mech-
anism will require studies with combina-
tions of agents or at least control of their
Figure 1—Regulation of gastric emptying.
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In addition to the above candidates,
GLP-1 inhibits gastric emptying (33). Its
secretion, however, is stimulated by the
intestinalnutrientcontentandﬂowrather
than by plasma glucose concentrations
themselves (34). Insulin and GLP1 secre-
tion in diabetes are impaired, and this
could also contribute to loss of the break
mechanism (36). Insulin itself may be an-
other regulator of gastric emptying in
healthysubjects(36);however,theeffects
of hyperinsulinemia on gastric emptying
were found to be marginal (36).
Taken together, these studies high-
light the importance of a delay in gastric
emptying response to hyperglycemia to
minimizing postprandial glucose excur-
sions, a defense mechanism not operative
inpatientswithtype1and2diabetesthat
may be at least partially explained by
hIAPP (27) and/or GLP1 deﬁciency (32)
or impaired suppression of ghrelin (18).
Perhaps a more sobering thought is what
would transpire if pramlintide or ex-
enatide were given to patients with auto-
nomic nerve dysfunction with reduction
in vagal activity. Would this lead to ob-
struction and bezoar formation, or would
the loss of vagal function be a failsafe de-
vice on which the actions of hIAPP and
GLP1 to slow gastric emptying are lost?
According to a case study report, a pa-
tientwithtype1diabetesandlong-term
complications (retinopathy, neuropa-
thy, and end-stage renal disease) who
had undergone a recent islet-after-
kidney transplant and was put on ex-
enatide for improving glycemic control
developed severe gastroparesis and
food content bezoar 11 months later.
Exenatide was stopped and restarted af-
terremovingthebezoarendoscopically,
but this was followed by recurrence of
gastrointestinal symptoms and another
gastric bezoar. Exenatide was discon-
tinued, and the patient’s condition
remained stable after intrapyloric botu-
linum injection (37).
Clearly, this is a very complex arena,
and further studies on the effects of inhibi-
tion of hIAPP (if and when an antagonist
becomes available) and the impact of auto-
nomic dysfunction might serve to resolve
someoftheseissues.Whateverthecase,the
authors have shed new light on the role of
hyperglycemia per se on vagal function and
the implications of hIAPP deﬁciency on the
brittle diabetes control of the patient with
type 1 diabetes. We can only conjecture
now on what the impact of a loss in the
brakemechanismwouldmeantotheaction
of hIAPP in diabetes (26).
One caveat is that the slowing of gas-
tric emptying seems to be of cardinal im-
portance in regulating postprandial
glycemia. However, there is another side
to the coin. The presence of autonomic
neuropathy slows gastric emptying and,
thus, the use of agents that embrace this
mechanism are fraught with the possibil-
ity of causing complications like obstruc-
tion and gastric bezoar formation. We
therefore conclude that if there is no
breakinthebrakemechanism,don’tﬁxit.
Beware of overzealous attempts to slow
gastric emptying when the mechanism is
broken.
AARON VINIK, MD
ARCHANA NAKAVE, MBBS
MARIA DEL PILAR SILVA CHUECOS, MD
From the Strelitz Diabetes Center, Eastern Virginia
Medical School, Norfolk, Virginia.
Corresponding author: Aaron I. Vinik,
vinikai@evms.edu.
DOI: 10.2337/dc08-1694
© 2008 by the American Diabetes Association.
Readers may use this article as long as the work is
properly cited, the use is educational and not for
proﬁt, and the work is not altered. See http://
creativecommons.org/licenses/by-nc-nd/3.0/ for
details.
●●●●●●●●●●●●●●●●●●●●●●●
References
1. Woerle HJ, Szoke E, Meyer C, Dostou JM,
Wittlin SD, Gosmanov NR, Welle SL,
Gerich JE: Mechanisms for abnormal
postprandial glucose metabolism in type
2 diabetes. Am J Physiol Endocrinol Metab
290:E67–E77, 2006
2. FrankJW,SaslowSB,CamilleriM,Thom-
forde GM, Dinneen S, Rizza RA: Mecha-
nism of accelerated gastric emptying of
liquids and hyperglycemia in patients
with type II diabetes mellitus. Gastroen-
terology 109:755–765, 1995
3. Stacher G: Diabetes and the stomach.
Dig Liver Dis 32 (Suppl. 3):S253–S254,
2000
4. Horowitz M, O’Donovan D, Jones KL,
Feinle C, Rayner CK, Samsom M: Gastric
emptying in diabetes: clinical signiﬁcance
and treatment. Diabet Med 19:177–194,
2002
5. Camilleri M: Clinical practice. Diabetic
gastroparesis.NEnglJMed356:820–829,
2007
6. Fraser RJ, Horowitz M, Maddox AF, Har-
dingPE,ChattertonBE,DentJ:Hypergly-
caemia slows gastric emptying in type 1
(insulin-dependent) diabetes mellitus.
Diabetologia 33:675–680, 1990
7. Woerle HJ, Albrecht M, Linke R, Zschau
S, Neumann C, Nicolaus M, Gerich J,
Goke B, Schirra J: Importance of changes
in gastric emptying for postprandial
plasma glucose ﬂuxes in healthy humans.
Am J Physiol Endocrinol Metab 294:E103–
E109, 2008
8. Schvarcz E, Palmer M, Aman J, Horowitz
M, Stridsberg M, Berne C: Physiological
hyperglycemia slows gastric emptying in
normalsubjectsandpatientswithinsulin-
dependent diabetes mellitus. Gastroenter-
ology 113:60–66, 1997
9. Kuo P, Rayner CK, Horowitz M: Gastric
emptying, diabetes, and aging. Clin Geri-
atr Med 23:785–808 2007
10. Chaikomin R, Rayner CK, Jones KL,
Horowitz M: Upper gastrointestinal func-
tionandglycemiccontrolindiabetesmel-
litus. World J Gastroenterol 12:5611–
5621, 2006
11. Gautier JF, Choukem SP, Girard J: Physi-
ology of incretins (GIP and GLP-1) and
abnormalities in type 2 diabetes. Diabetes
Metab 34 (Suppl 2):S65–S72, 2008
12. SchirraJ,NicolausM,RoggelR,Katschinski
M, Storr M, Woerle HJ, Goke B: Endoge-
nous glucagon-like peptide 1 controls en-
docrine pancreatic secretion and antro-
pyloro-duodenal motility in humans. Gut
55:243–251, 2006
13. Young A: Inhibition of gastric emptying.
Adv Pharmacol 52:99–121, 2005
14. Patil CS, Singh VP, Jain NK, Kulkarni SK:
Inhibitory effect of sildenaﬁl on gastroin-
testinalsmoothmuscle:roleofNO-cGMP
transduction pathway. Indian J Exp Biol
43:167–171, 2005
15. Orihata M, Sarna SK: Inhibition of nitric
oxide synthase delays gastric emptying of
solid meals. J Pharmacol Exp Ther 271:
660–670, 1994
16. Achem-KaramSR,FunakoshiA,VinikAI,
Owyang C: Plasma motilin concentration
and interdigestive migrating motor com-
plex in diabetic gastroparesis: effect of
metoclopramide. Gastroenterology 88:492–
499, 1985
17. Beales IL, Calam J: Regulation of amylin
releasefromculturedrabbitgastricfundic
mucosal cells. BMC Physiol 3:13, 2003
18. Fujino K, Inui A, Asakawa A, Kihara N,
FujimuraM,FujimiyaM:Ghrelininduces
fasted motor activity of the gastrointesti-
nal tract in conscious fed rats. J Physiol
550:227–240, 2003
19. Ariga H, Imai K, Chen C, Mantyh C, Pap-
pas TN, Takahashi T: Does ghrelin ex-
plain accelerated gastric emptying in the
early stages of diabetes mellitus? Am J
Physiol Regul Integr Comp Physiol 294:
R1807–R1812, 2008
20. Berthoud HR: Vagal and hormonal gut-
brain communication: from satiation to
satisfaction. Neurogastroenterol Motil 20
(Suppl. 1):64–72, 2008
21. Cai XJ, Evans ML, Lister CA, Leslie RA,
Arch JR, Wilson S, Williams G: Hypogly-
cemia activates orexin neurons and se-
lectively increases hypothalamic orexin-B
levels: responses inhibited by feeding
Brake mechanism and postprandial glycemia
2412 DIABETES CARE, VOLUME 31, NUMBER 12, DECEMBER 2008and possibly mediated by the nucleus of
the solitary tract. Diabetes 50:105–112,
2001
22. Schvarcz E, Palmer M, Aman J, Berne C:
Atropine inhibits the increase in gastric
emptying during hypoglycemia in hu-
mans.DiabetesCare18:1463–1467,1995
23. Ishiguchi T, Tada H, Nakagawa K,
Yamamura T, Takahashi T: Hyperglyce-
mia impairs antro-pyloric coordination
and delays gastric emptying in conscious
rats. Auton Neurosci 95:112–120, 2002
24. Bertin E, Schneider N, Abdelli N, Wam-
pach H, Cadiot G, Loboguerrero A, Leu-
tenegger M, Liehn JC, Thieﬁn G: Gastric
emptying is accelerated in obese type 2
diabetic patients without autonomic neu-
ropathy. Diabetes Metab 27:357–364,
2001
25. Woerle HJ, Albrecht M, Linke R, Zschau
S, Neumann C, Nicolaus M, Gerich JE,
Go ¨ke B, Schirra J: Impaired hyperglyce-
mia-induced delay in gastric emptying in
patients with type 1 diabetes deﬁcient for
islet amyloid polypeptide. Diabetes Care
31:2325–2331, 2008
26. Fehmann HC, Weber V, Goke R, Goke B,
Arnold R: Cosecretion of amylin and in-
sulinfromisolatedratpancreas.FEBSLett
262:279–281, 1990
27. Young A: Unresponsiveness in gastric
emptying contributes to postprandial hy-
perglycemia in type 1 diabetes. Inhibition
of gastric emptying. Adv Pharmacol 52:
99–121, 2005
28. Schmitz O, Brock B, Rungby J: Amylin
agonists: a novel approach in the treat-
ment of diabetes. Diabetes 53 (Suppl 3):
S233–S238, 2004
29. Ludvik B: [Amylin/IAPP (islet amyloid
polypeptide)–physiology and clinical sig-
niﬁcance]. Wien Klin Wochenschr 109:
379–383, 1997
30. Samsom M, Szarka LA, Camilleri M, Vella
A,ZinsmeisterAR,RizzaRA:Pramlintide,
an amylin analog, selectively delays gas-
tric emptying: potential role of vagal inhi-
bition. Am J Physiol Gastrointest Liver
Physiol 278:G946–G951, 2000
31. Woerle HJ, Mariuz PR, Meyer C, Reich-
man RC, Popa EM, Dostou JM, Welle SL,
Gerich JE: Mechanisms for the deteriora-
tion in glucose tolerance associated with
HIV protease inhibitor regimens. Diabetes
52:918–925, 2003
32. le Roux CW, Patterson M, Vincent RP,
Hunt C, Ghatei MA, Bloom SR: Postpran-
dial plasma ghrelin is suppressed propor-
tional to meal calorie content in normal-
weight but not obese subjects. J Clin
Endocrinol Metab 90:1068–1071, 2005
33. Schirra J, Leicht P, Hildebrand P, Beg-
linger C, Arnold R, Goke B, Katschinski
M: Mechanisms of the antidiabetic action
of subcutaneous glucagon-like peptide-
1(7–36)amide in non-insulin dependent
diabetes mellitus. J Endocrinol 156:177–
186, 1998
34. Schirra J, Katschinski M, Weidmann C,
Schafer T, Wank U, Arnold R, Goke B:
Gastric emptying and release of incretin
hormones after glucose ingestion in hu-
mans. J Clin Invest 97:92–103, 1996
35. Vollmer K, Holst JJ, Baller B, Ellrichmann
M,NauckMA,SchmidtWE,MeierJJ:Pre-
dictors of incretin concentrations in sub-
jects with normal, impaired, and diabetic
glucose tolerance. Diabetes 57:678–687,
2008
36. Kong MF, King P, Macdonald IA, Black-
shaw PE, Perkins AC, Armstrong E,
Buchanan KD, Tattersall RB: Effect of eu-
glycaemic hyperinsulinaemia on gastric
emptying and gastrointestinal hormone
responsesinnormalsubjects.Diabetologia
41:474–481, 1998
37. Ahmad SR, Swann J: Exenatide and rare
adverse events. N Engl J Med 358:1970–
1971, 2008
Vinik, Nakave, and del Pilar Silva Chucos
DIABETES CARE, VOLUME 31, NUMBER 12, DECEMBER 2008 2413